Chronic Lymphocytic Leukemia Drug Treatment Shows Promise 
MyHealthNewsDaily
An experimental drug, called ibrutinib, shows promise treating elderly patients with chronic lymphocytic leukemia, according to preliminary findings from a phase I/II clinical trial. Clinical trial results do not always hold up in later studies.
Ibrutinib shows promise against CLL in the elderly News-Medical.net
Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib ... MarketWatch (press release)

all 18 news articles » 

Cyclacel to Report New Sapacitabine Clinical Data at the American Society of ... 
MarketWatch (press release)
... acute myeloid leukemia (AML), Phase 2 trials in patients with hematological malignancies, including myelodysplastic syndromes (MDS), cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), ...

and more » 

Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete ... 
MarketWatch (press release)
Blinatumomab is the first of the BiTE antibodies and Amgen has received orphan drug designation from the US Food and Drug Administration for the treatment of ALL, chronic lymphocytic leukemia (CLL), hairy cell leukemia, prolymphocytic leukemia and ...

and more » 

Identifying Aggressive Leukemia 
dailyRx
There are two main types of chronic lymphocytic leukemia, and knowing whether a patient has the aggressive or the slow version is very important to determine treatment early on. New research from the University of California-San Diego School of ...

and more » 

Donate your empties to fight leukemia 
insideTORONTO.com
"I am facing a new battle now, alongside thousands of other Canadians - leukemia." Henderson was diagnosed with chronic lymphocytic leukemia (CLL) in November 2009. CLL is the leading type of leukemia diagnosed in Canadian adults.

and more » 

Genmab Announces Financial Results for the First Quarter 2012 
MarketWatch (press release)
April: GSK submitted a NDA for ofatumumab to regulatory authorities in Japan for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior treatment. Genmab is maintaining its 2012 financial guidance as announced on ...

and more » 

Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment ... 
MarketWatch (press release)
GS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being evaluated in combination with rituximab in previously treated chronic lymphocytic leukemia (CLL) patients.

and more » 

Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent ... 
MarketWatch (press release)
Oral Presentation Date/Time: Monday, June 4, 2012; 10:15 AM - 10:30 AM (CT) Location: E354a Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naïve chronic lymphocytic leukemia patients: Interim results of a phase Ib/II ...

and more » 

TG Therapeutics, Inc. Announces Investigational New Drug (IND) for TGTX-1101 ... 
MarketWatch (press release)
Ublituximab has displayed high single agent activity in a Phase 1/2 clinical trial in patients with relapsed Chronic Lymphocytic Leukemia, and is being developed by TG Therapeutics in multiple oncology and autoimmune indications.

and more » 

Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2 ... 
MarketWatch (press release)
... acute myeloid leukemia (AML), Phase 2 trials in patients with hematological malignancies, including myelodysplastic syndromes (MDS), cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), ...

and more »